Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Actelion initiates RESTORA 1 phase III study of almorexant for primary insomnia

Dec. 28, 2007

Update on Intra-Cellular Therapies' ITI-007/ITI-722 for schizophrenia and SMI

Dec. 28, 2007

Novel therapeutic agents for Alzheimer's disease disclosed in recent patent literature

Dec. 28, 2007

Elan and Transition Therapeutics initiate dosing in phase II clinical study of ELND-005 for AD

Dec. 27, 2007

First patient dosed in phase III program for bapineuzumab in Alzheimer's

Dec. 27, 2007

Kalypsys initiates phase IIa clinical trial of KD-7040 for postherpetic neuralgia

Dec. 27, 2007

SK-PC-B70M reverses scopolamine-induced memory deficits in vivo

Dec. 27, 2007

Adjunctive N-acetyl cysteine beneficial in schizophrenia patients

Dec. 27, 2007

FDA issues approvable letter for Jazz Pharmaceuticals' Luvox for SAD and OCD

Dec. 24, 2007

VGF neuropeptide gene involved in antidepressant effects of exercise

Dec. 24, 2007

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...